Podcasts about cardiac

The chain of survival for ACLS is the same as was learned in your BLS class.The beginning steps of the Cardiac Emergency and Stroke chain of survival.ACLS's timed goals for first medical contact to PCI for STEMI and door-to-needle for ischemic stroke.Characteristics of areas that have significantly better stroke and out-of-hospital cardiac arrest outcomes.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vipPass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Cardiac arrest remains one of the leading causes of death worldwide, striking without warning and demanding urgent emergency response. In this episode of The Health Technology Podcast, we spotlight cardiac arrest prevention, portable defibrillator innovation, and next-generation AED technology featuring Sameer Jafri, CEO and co-founder of Avive Solutions. From his early days volunteering at cardiac screenings to founding a nonprofit focused on heart health at UCLA, Sameer's dedication to life-saving innovation has always been personal. With Avive Solutions, he is pioneering the development of connected, portable AEDs, making advanced emergency response accessible in homes, schools, sports fields, and public spaces everywhere. Sameer shares how Avive's smart defibrillator ecosystem is changing outcomes by bridging the gap between bystanders and medical professionals. By integrating real-time data and rapid response capabilities, Avive's technology empowers communities to act decisively and improve cardiac arrest survival rates. Whether you're a healthcare innovator, a clinician, or someone passionate about medical technology, this episode reveals what it takes to challenge the status quo in cardiac care. Tune in to hear how Sameer Jafri is transforming the future of emergency medicine through connected devices, better access, and relentless advocacy for cardiac arrest prevention. Do you have thoughts on this episode or ideas for future guests? We'd love to hear from you. Email us at hello@rosenmaninstitute.org.

N Engl J Med 2001;345:1667-1675Background: Angiotensin II is a peptide hormone that is part of the renin–angiotensin–aldosterone system (RAAS). Angiotensin II is a potent vasoconstrictor and growth-stimulating hormone. Data suggested that it plays a role in ventricular remodeling and progression of heart failure. Although treatment with angiotensin-converting enzyme inhibitors (ACEi) reduce angiotensin II levels, physiologically active levels of angiotensin II may persist despite long-term therapy.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Valsartan Heart Failure Trial (Val-HeFT) sough to assess whether the angiotensin-receptor blocker valsartan, could reduce mortality and morbidity when added to optimal medical therapy in patients with systolic heart failure.Patients: Eligible patients had left ventricular ejection fraction less than 40% and left ventricular dilation, in addition to having clinical heart failure for at least 3 months with NYHA class II, III or IV symptoms. Patient also had to have been receiving a fixed-dose drug regimen for at least two weeks, that could include ACEi, diuretics, digoxin, and beta-blockers.There were many exclusion criteria. We mention some here: Postpartum cardiomyopathy, acute myocardial infarction within 3 months, coronary artery disease likely to require intervention, serum creatinine >2.5 mg/dL and life expectancy less than 5 years.Baseline characteristics: Patients were recruited from 302 centers in 16 countries. The trial randomized 5,010 patients – 2,511 randomized to receive valsartan and 2,499 to receive placebo.The average age of patients was 63 years and 80% were men. The average left ventricular ejection fraction was 27%. Cardiomyopathy was ischemic in 57% of the patients. The NYHA class was II in 62% of the patients, III in 36% of the patients and IV in 2%.Approximately 26% had diabetes and 12% had atrial fibrillation.At the time of enrollment, 86% were taking a diuretic, 67% were taking digoxin, 35% were taking beta-blockers, and 93% were taking ACEi.Procedures: The trial was double-blinded. The trial had an initial run-in period for 2 - 4 weeks where patients received placebo twice daily. This was performed to confirm patients' eligibility, clinical stability and compliance.Patients were assigned in a 1:1 ratio to receive valsartan or placebo. Randomization was stratified according to whether or not they were receiving a beta-blocker.Valsartan was started at a dose of 40 mg twice a day, and the dose was doubled every two weeks to the target dose of 160 mg twice a day. Placebo doses were adjusted in a similar way.Follow up occurred at 2, 4, and 6 months and every 3 months thereafter.Endpoints: The trial had two primary end points. The first was all-cause mortality. The second was the combined end point of mortality and morbidity, which was defined as cardiac arrest with resuscitation, hospitalization for heart failure, or administration of intravenous inotropic or vasodilator drugs for four hours or more without hospitalization.The estimated sample size was 5,000 patients. The sample size calculation assumed 20% relative risk reduction in mortality with valsartan assuming 906 patients would die during the trial. This sample size would provide the trial 90% power at 0.02 alpha. Alpha was 0.02 instead of the traditional 0.05 since the trial had two primary endpoints and to adjust for the interim analyses.Results: The target valsartan dose of 160 mg twice a day was achieved in 84% of the patients. The reduction in systolic blood pressure was greater with valsartan vs placebo – mean of 5.2 ± 15.8 mm with valsartan compared to 1.2 ± 14.8 mm Hg with placebo, at 4 months.All-cause mortality was not different between both groups (19.7% with valsartan vs 19.4% with placebo, RR: 1.02, 95% CI: 0.88 – 1.18; p= 0.80). The second co-primary endpoint was reduced with valsartan (28.8% vs 32.1%, RR: 0.87, 95% CI: 0.77 – 0.97; p= 0.009). This was driven by reduction in hospitalizations for heart failure (13.8% vs 18.2%). Cardiac arrest with resuscitation was 0.6% with valsartan and 1.0% with placebo. All-cause hospitalization was numerically lower with valsartan, however, this was not statistically significance (2,856 vs 3,106; p= 0.14). The mean change in ejection fraction was higher with valsartan (4.0% vs 3.2%; p= 0.001). More patients had improvement in NYHA classification with valsartan (23.1% vs 20.7%; p

Steve, Jeff, and Charlie played their daily "Triple Option" segment. Steve celebrated Saints running back Alvin Kamara's outstanding career on "Flashback Friday." Jeff reviewed a strange stat about Saints TE Juwan Johnson. Charlie celebrated Indiana's improbable comeback in Game 1 of the 2025 NBA Finals.

JD reacts to the historic comeback win from the Indiana Pacers and Tyrese Haliburton (00:00). JD then goes through his feelings following the report of Mitch Marner, his relationship with the Maple Leafs and his looming free-agency (20:00). The show ends with JD's gripes following the news of Aaron Rodgers finally signing with the Pittsburgh Steelers (34:00), along with Gary Bettman addressing the media. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.  

Adenosine is the first IV medication given to stable patients with sustained supraventricular tachycardia (SVT) refractory to vagal maneuvers.Symptoms indicating a stable vs unstable patient.Common causes of tachycardia.Cardiac effects of Adenosine. Indications for use in the ACLS Tachycardia algorithm.Considerations and contraindications. Adenosine as a diagnostic for patients in A-Fib or A-Flutter with RVR.Dosing and administration.Other podcasts that cover common ACLS antiarrhythmics in more detail and another covering Brugata Criteria used to differentiate V-Tach from SVT with an aberrancy, can be found on the Pod Resources page at passacls.com.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vipPass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

America Out Loud PULSE with Dr. Mary Talley Bowden – By leveraging advanced mathematical algorithms and artificial intelligence, the MCG detects small vessel disease and ischemia — conditions where tiny heart vessels lack sufficient oxygenation. Identifying early heart disease and potentially preventing heart attacks by addressing small vessel issues before they progress...

Send us a textIn this episode of The Daily Apple, Dr. John Osborne and JD Enright from Clear Cardio join Kevin to talk about something that affects literally everyone with a heartbeat: heart disease. But instead of waiting until the heart attack hits, they're flipping the script and focusing on prevention—with a little help from cutting-edge AI.They dive into how artificial intelligence is changing the game in cardiac imaging, how to actually understand the difference between soft and hard plaque (yes, it matters), and why lifestyle changes aren't just good advice—they're lifesaving.

America Out Loud PULSE with Dr. Mary Talley Bowden – By leveraging advanced mathematical algorithms and artificial intelligence, the MCG detects small vessel disease and ischemia — conditions where tiny heart vessels lack sufficient oxygenation. Identifying early heart disease and potentially preventing heart attacks by addressing small vessel issues before they progress...

Episode 192: ADHD Treatment.  Jordan Redden (MSIV) explains the treatment of ADHD. Dr. Bustamante adds input about pharmacologic and non-pharmacologic treatments. Dr. Arreaza shares the how stimulants were discovered as the treatment for ADHD. Written by Jordan Redden, MSIV, Ross University School of Medicine. Comments and edits by Isabelo Bustamante, MD, and Hector Arreaza, MD. You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Introduction.ADHD is a chronic neurodevelopmental condition characterized by inattention, impulsivity, and/or hyperactivity. While it's often diagnosed in childhood, symptoms can persist well in adulthood. The treatment for ADHD is multifaceted. It often includes medication, behavioral therapy, environmental modifications, and sometimes educational interventions which are especially effective in younger patients. Ongoing evaluation is needed during treatment. Treatment needs adjustments over time.Starting with medications: Stimulants are the most well-studied and effective pharmacologic treatment for ADHD. These include methylphenidate-based medications such as Ritalin, Concerta, and Focalin, and amphetamine-based options, like Adderall, Vyvanse, and Dexedrine. Discovery of stimulants for ADHD> Dr. Charles Bradley discovered stimulants as the treatment for ADHD around 1937. ADHD did not have a name at that time, but it was known that some children had behavioral problems related to poor attention and inability to control their impulses, but they were still intelligent. Dr. Bradley was a psychiatrist who was working in the Bradley Hospital (Rhode Island), he was studying these children and, as part of his experiments, they developed severe headaches. He gave “Benzedrine” (a decongestant) to his pediatric patients to treat severe headaches, and he discovered that Benzedrine improved academic performance and interest in school and improved disruptive behavior in some children.How do stimulants work.Stimulants work primarily by increasing dopamine and norepinephrine levels in the brain, which helps improve focus, attention span, and impulse control. They typically show a rapid onset of action and can lead to noticeable improvements within the first few days of use. Dosing is individualized and should start low with gradual titration. Side effects can include reduced appetite, insomnia, headaches, increased heart rate, and emotional lability.Types of stimulants. Stimulants come as short acting and long acting. They can come as a tablet, liquid, patch, or orally disintegrating tablet. After the discovery of Benzedrine as a possible treatment for ADHD, more research was done over the years, and Ritalin became the first FDA-approved medication for ADHD (1955). The list of medications may seem overwhelming, but there are only two types of stimulants used to treat ADHD: methylphenidate and amphetamine. Long-acting stimulant medications are often preferred for their consistent symptom control and lower potential for misuse. Vyvanse (lis-dexa-mfetamine) is a widely used long-acting amphetamine-based option. As a prodrug, it remains inactive until metabolized in the body, which results in a smoother onset and offset of action and may reduce the risk of abuse. This extended duration of effect can help patients maintain focus and regulate impulses throughout the day without the peaks and crashes sometimes seen with shorter-acting formulations. Of note, Vyvanse is also approved for Binge Eating Disorder. Many of these medications are Schedule II controlled substances, so to prescribe them you need a DEA license. Other long-acting options include Concerta, an extended-release methylphenidate, as well as extended-release versions of Adderall and Focalin. These are especially helpful for school-aged children who benefit from once-daily dosing, and for adults who need sustained attention during work or academic activities. The choice between short- and long-acting stimulants depends on individual response, side effect tolerance, and daily routine.For patients who cannot tolerate stimulants, or for those with contraindications such as a history of substance misuse or certain cardiac conditions, non-stimulant medications are an alternative. One of the most used is atomoxetine, which inhibits the presynaptic norepinephrine transporter (NET). This leads to increased levels of norepinephrine (and to a lesser extent dopamine). Guanfacine or clonidine are alpha-2A adrenergic receptor agonists that lead to reduced sympathetic outflow and enhanced prefrontal cortical function, improving attention and impulse control. These alpha agonists are particularly useful in younger children with significant hyperactivity or sleep disturbances.Non-pharmacologic treatments.Behavioral therapy before age 6 is the first choice, after that, medications are more effective than BH only, and as adults again you use CBT.Medication is often just one part of a broader treatment plan. Behavioral therapy, especially in children, plays a critical role. Parent-training programs, positive reinforcement systems, and structured routines can significantly improve functioning. And for adolescents and adults, cognitive-behavioral therapy (CBT) is particularly helpful. CBT can address issues like procrastination, time management, emotional regulation, and self-esteem which are areas that medication doesn't always touch.Using medications for ADHD can be faced with resistance by parents, and even children. There is stigma and misconceptions about mental health, there may be concerns about side effects, fear of addiction, negative past experiences, and some parents prefer to treat ADHD the “natural” way without medications or only with supplements. All those concerns are valid. Starting a medication for ADHD is the first line of treatment in children who are 6 years and older, but it requires a shared decision with parents and patients. Cardiac side effects are possible with stimulants. EKG may be needed before starting stimulants, but it is not required. Get a personal and family cardiac history, including a solid ROS. Benefits include control of current condition and treating comorbid conditions.The presentation of ADHD changes as the person goes through different stages of life. For example, you may have severe hyperactivity in your school years, but that hyperactivity improves during adolescence and impulsivity worsens. It varies among sexes too. Women tend to present as inattentive, and men tend to be more hyperactive. ADHD is often underdiagnosed in adults, yet it can significantly impact job performance, relationships, and mental health. In adults, we often use long-acting stimulants to minimize the potential for misuse. And psychotherapy, particularly CBT or executive functioning coaching, can be life-changing when combined with pharmacologic treatment. There are several populations where treatment must be tailored carefully such as pregnant patients, individuals with co-occurring anxiety or depression, and those with a history of substance use. For example, atomoxetine may be preferred in patients with a history of substance misuse. And in children with coexisting oppositional defiant disorder, combined behavioral and pharmacologic therapy is usually more effective than either approach alone.Comorbid conditions.Depression and anxiety can be comorbid, and they can also mimic ADHD. Consult your DSM-5 to clarify what you are treating, ADHD vs depression/anxiety.Treatment goes beyond the clinic. For school-aged children, we often work closely with schools to implement 504 plans or Individualized Education Programs (IEPs) that provide classroom accommodations. Adults may also benefit from workplace strategies like structured schedules, noise-reducing headphones, or even coaching support. Ongoing monitoring is absolutely essential. We assess side effects of medication, adherence, and symptom control. ***In children, we also monitor growth and sleep patterns. We often use validated rating scales, like the Vanderbilt questionnaire for children 6–12 (collect answers from two settings) or Conners questionnaires (collect from clinician, parents and teachers), to track progress. And shared decision-making with patients and families is key throughout the treatment process.To summarize, ADHD is a chronic but manageable condition. Effective treatment usually involves a combination of medication and behavioral interventions, tailored to the individual's needs. And early diagnosis and treatment can significantly improve quality of life academically, socially, and emotionally.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed., text rev. (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022. CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder). Understanding ADHD. Accessed May 2025. https://chadd.org National Institute for Health and Care Excellence (NICE). Attention Deficit Hyperactivity Disorder: Diagnosis and Management. NICE guideline [NG87]. Updated March 2018. Accessed May 2025. https://www.nice.org.uk/guidance/ng87 Pliszka SR; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894–921. doi:10.1097/chi.0b013e318054e724 Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):e20192528. doi:10.1542/peds.2019-2528 Texas Children's Hospital. ADHD Provider Toolkit. Baylor College of Medicine. Accessed May 2025. https://www.bcm.edu Wolraich ML, Hagan JF Jr, Allan C, et al. Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis. UpToDate. Published 2024. Accessed May 2025.https://www.uptodate.comThe History of ADHD and Its Treatments, https://www.additudemag.com/history-of-adhd/Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. 

  Nuclear Medicine Physics ToolsAndrew Chacon @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}In this podcast, we chat to Andrew Chacon at the ANZSNM, who has made a great set of tools for everyone to download and use for physicists, technologists, doctors, and everyone in nuclear medicine. Links below.  https://github.com/achacon01/nuclearMedicineToolsWebsitehttps://achacon01.github.io/nuclearMedicineToolsWebsite/index.htmlTAGS ANZSNM25,PET,Podcast,Nuclear,Imaging,Therapy,NuclearMedicine,NIF,Physics,UNIMELB,MBCIU,Positron,NUCCAST,AI,Austin @font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-469750017 -1040178053 9 0 511 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-font-kerning:1.0pt; mso-ligatures:standardcontextual; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;} Please let me know what you think about the video versions of the podcast.I am also looking for new material so please get in touch with me if you can contributewith an interview.Direct link to iTuneshttps://itunes.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicinie-podcast/id1444565219?mt=2Older podcastshttps://podcasts.apple.com/au/podcast/the-nuclear-medicine-and-molecular-medicine-podcast/id94286547You can get the podcast page at both http://nuccast.com and http://www.nuccast.com with the feed to put into iTunes or juice or your favourite podcast software can be found at http://molcast.com/.The cardiac subset of the podcast can be found at http://cardiac.nuccast.com/Please pass on information about this podcast to your colleagues and to your CPD provider.Link to Video Link to Video fileLink to Audio file Link to Audio fileOr you can subscribe by entering your email address below and you will be informed of new episodesEnter your email address:Delivered by FeedBurnerMost importantly of all please help this podcast by contributing your opinions, Sound files, and emailsnucmedpodcast@gmail.comAll contributions welcome, especially as sound files to nucmedpodcast@gmail.com.@font-face {font-family:"Cambria Math"; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1107305727 0 0 415 0;}p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0cm; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman",serif; mso-fareast-font-family:"Times New Roman";}.MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-family:"Calibri",sans-serif; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin; mso-bidi-font-family:"Times New Roman"; mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-GB; mso-fareast-language:EN-US;}div.WordSection1 {page:WordSection1;}

Dr. Jeff Wessler, a cardiologist and CEO and co-founder of Heartbeat Health; and William Krenz, senior vice president of government programs for Regence, discuss how Heartbeat and Regence are using virtual cardiac care to improve heart health and cardiac care for Regence members.  

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Systolic and Diastolic Blood Pressure, Cardiac Biomarkers, and Cardiovascular Mortality in Adults Without Cardiovascular Disease.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Cardiac Output Estimation in the Intensive Care Unit.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Very Long-Term Outcomes of Cardiac Resynchronization Therapy in Patients With Ischemic and Nonischemic Cardiomyopathy.

This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Dr. Matthew Elias discusses various treatments and innovations in cardiac care that can save and iprove the lives of children with heart disease worldwide. 1 in every 110 babies in the U.S. is born with heart disease. Georgene Summers talks about her book Angels in Sin: Mayhem, Money, and Murder. A memoir filled with romance, true crime, and isnpiration.A risk-filled exciting, dangerous, andventurous story!

Dr. Matthew Elias discusses various treatments and innovations in cardiac care that can save and iprove the lives of children with heart disease worldwide. 1 in every 110 babies in the U.S. is born with heart disease. Georgene Summers talks about her book Angels in Sin: Mayhem, Money, and Murder. A memoir filled with romance, true crime, and isnpiration.A risk-filled exciting, dangerous, andventurous story!

This episode is a replay of a live webinar by cardiac CRNA, Alex Gorman, who gives an excellent presentation on Cardiac Anesthesia. He explores the essentials for managing complex heart cases in the OR. We walk through the entire process—from pre-op evaluations and cath report interpretation to hemodynamic management and weaning off bypass. Whether you're a CRNA, resident, or ICU nurse, you'll gain valuable insight into real-world decision-making, including drug selection, TEE basics, and how to collaborate effectively with perfusionists and surgeons. This episode is packed with tips to help you feel more prepared and confident in cardiac rotations, and we share actionable advice on soft skills that can make or break your clinical experience. Stick around until the end to learn the one mistake you should never make with protamine—and how it could be fatal if you do.

Contributor: Travis Barlock, MD Educational Pearls: Wheezing is classically heard in asthma and COPD, but it can be the result of a wide range of processes that cause airflow limitation Narrowed bronchioles lead to turbulent airflow → creates the wheezing Crackles (rales) suggest pulmonary edema which is often due to heart failure Approximately 35% of heart failure patients have bronchial edema, which can also produce wheezing COPD and heart failure can coexist in a patient, and both of these diseases can cause wheezing It's vital to differentiate whether the wheezing is due to the patient's COPD or their heart failure because the treatment differs Diagnosing wheezing due to heart failure (cardiac asthma): Symptoms: orthopnea, paroxysmal nocturnal dyspnea Diagnostic tools: bedside ultrasound Treatment: diuresis and BiPAP for respiratory support Not all wheezing is asthma Consider heart failure in the differential and tailor treatment accordingly References 1. Buckner K. Cardiac asthma. Immunol Allergy Clin North Am. 2013 Feb;33(1):35-44. doi: 10.1016/j.iac.2012.10.012. Epub 2012 Dec 23. PMID: 23337063. 2. Hollingsworth HM. Wheezing and stridor. Clin Chest Med. 1987 Jun;8(2):231-40. PMID: 3304813. Summarized by Meg Joyce, MS1 | Edited by Meg Joyce & Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

In this conversation, Dr. Peter Weimersheimer discusses various techniques and tips for performing cardiac ultrasound in emergency medicine. He emphasizes the importance of understanding probe movements such as sliding, fanning, and rocking to optimize cardiac views. The discussion also covers troubleshooting common challenges in cardiac imaging, the critical role of gel in obtaining clear images, and the transition between different cardiac views. Dr. Weimersheimer emphasizes the importance of identifying cardiac pathologies through ultrasound and shares techniques for obtaining the apical four-chamber view. The conversation concludes with insights into the impact of ultrasound on patient care and decision-making in emergency situations. In this conversation, Dr. Peter Weimersheimer shares his expertise on cardiac ultrasound techniques, with a focus on the apical four-chamber view and the importance of understanding ventricular shape and function. He discusses practical tips for navigating ultrasound views in critical situations, optimizing imaging techniques, and utilizing patient physiology to enhance imaging quality. The conversation also covers the interpretation of right ventricular size in cardiac arrest and differentiating between the inferior vena cava (IVC) and aorta during ultrasound imaging.

Commentary by Dr. Jian'an Wang.

AABP Executive Director Dr. Fred Gingrich reviews a paper published in The Bovine Practitioner with the first author Madeline Mancke from Kansas State University. The objective of this study was to determine potential associations between Cardiac Troponin I (cTnI) serum concentration of cattle at initial bovine respiratory disease (BRD) treatment with the risk of retreatment or mortality at 60 days. BRD is the most significant disease in beef cattle and is a major cause of morbidity and mortality. Developing prognostic tools may be valuable for managing individual cases. cTnI is a protein that is released into the circulatory system after myocardial damage and may be useful as a biomarker for prognostication of BRD cases. Mancke walks through the results of the paper which demonstrated that 8/318 samples had high cTnI levels and animals with high cTn1 concentrations had a significantly greater probability of not finishing the 60-day post-enrollment period. Cattle with high cardiac troponin concentrations at initial BRD treatment were more likely to have negative clinical outcomes but, in this study, very few animals had high cTnI levels. Mancke provides information about potential future research opportunities to better manage BRD cases in the feedyard.  The Bovine Practitioner is the peer-reviewed journal published by AABP. The journal publishes original research, case studies, review articles and case studies that are intended to provide information to the practicing cattle veterinarian. The journal is available open-access online and print volumes are available for purchase. There are no publication fees for authors and the peer review and submission process is managed online. Find the journal at this link.  Evaluation of cardiac troponin I as a predictor of clinical outcomes in cattle treated for bovine respiratory disease (BRD) in commercial feedyards. Bov Pract. 2025;59(1), 24-28. https://doi.org/10.21423/bpj20259053 

Despite our couch potato reputation, more people are running marathons in the U.S. In…

Welcome, MedTech Gurus! Imagine a future where rural communities have the same access to advanced cardiac diagnostics as major metropolitan hospitals… where early-stage heart disease is caught before it becomes an emergency… and where the wearable on your chest does more than just collect data—it helps rewrite your health journey. That future is now, and today's guest, Chris Darland, CEO of PeerBridge Health, is at the heart of it. Chris and his team are bringing next-generation wearable cardiac monitors to life with CoreMDX—an ambulatory ECG system that delivers hospital-grade signal fidelity and real-time insights, all in a user-friendly patch. In this episode, we dive into how PeerBridge is transforming early disease detection, enabling virtual cardiology, and solving the readmission crisis with scalable, affordable tech. We'll also explore how vintage scientific breakthroughs are being reimagined with cutting-edge AI, and what it really takes to raise capital in today's medtech landscape. This is an episode on innovation you will love!

Focus Issue on Cardiac and Vascular Surgery and Arrhythmias

An Irish cardiac tech company has announced it is to create 20 jobs over the next three years, while targeting an additional €3m in revenue, as it expands overseas. The Louth based business will also be rebranding as Heart Rhythm International will initially target the UK, where they expect to add 30 additional hospitals and approximately 50,000 additional patients to their network before 2029. They will also be looking to bring their innovative cardiac care solution to Australia/ New Zealand and the US health markets in the coming years. Previously known as Heart Rhythm Ireland, the company operates a cloud-based cardiac rhythm management platform that supports patients as well as hospitals, clinicians and cardiac device manufacturers. Their system makes patient cardiac device information available in real time, delivering accurate, accessible and actionable data to patients and their medical teams. This improves patient outcomes by making device data more accessible, enabling timely clinical decisions and more coordinated care. HRI's system also provides patients with secure access to their information anytime and anywhere, making it easier to share critical data with healthcare providers in emergencies. The company is currently developing AI and predictive analytics capabilities, which are expected to further enhance the platform by supporting earlier insights and more personalised cardiac care in the future. Heart Rhythm International already supports over 65,000 patients across Ireland, with its platform in use at more than 50 cardiac hospitals nationwide. The company provides national coverage, working with leading institutions such as the Mater Misericordiae University Hospital, Bon Secours Health System, Beaumont Hospital, Mater Private Network, University Hospital Galway, Blackrock Health, and Cork University Hospital. HRI expects to grow its team to 30 personnel in the coming years. For more than 15 years, HRI has served as Ireland's national electronic health record for cardiac devices, maintaining a registry of over 100,000 implant procedures and nearly one million clinical follow-up records. Alongside its commercial expansion, HRI is actively contributing to international research and innovation projects. It is a partner in Project CARAMEL, a €12 million initiative funded under the EU Horizon Europe programme, helping to develop AI-powered predictive models for cardiovascular risk in women aged 40 to 60. HRI is also an industry partner in the new Health Frontiers Technology Innovation Centre (HF-TIC), led by Ulster University and supported by €9.1 million in PEACEPLUS funding. Both initiatives reinforce HRI's leadership in AI-driven digital health innovation on an international scale. "Every 20 seconds, someone receives a cardiac implant, but the systems supporting their care haven't kept pace," said Robert Kelly, CEO of HRI. "HRI was set up to change that, by operating at the centre of a unique eco-system, supporting patients, hospitals and clinicians and cardiac device manufacturers. Through our system, patients receive greater peace of mind and better health outcomes, while medical personnel can make better-informed and more efficient decisions. Ultimately that improves patient care and helps save lives. "We've already demonstrated how we can enhance cardiac care in Ireland by supporting over 65,000 patients and working with more than 50 hospitals nationwide. Now, we're bringing that capability overseas. A key strength of our system is that it was built on scalable, cloud-based infrastructure in partnership with IBM, allowing it to be rapidly deployed by healthcare providers anywhere in the world." "We're managing our expansion step by step, focusing initially on the UK market. However, we are already discussing partnerships and opportunities with healthcare providers in the US and Australia/ New Zealand. We believe there is real opportunity for HRI to grow, to support more patients and doctors overseas, whi...

The heart is an involved organ in many syndromes impacting kids. Our understanding of the genetic underpinnings of pediatric heart conditions has improved greatly with better access to genetic testing. From inherited arrythmias to structural congenital heart defects, genetic testing is becoming an essential part of the diagnosis, treatment and family counseling in kids with heart problems. To help us understand this evolving field, we are joined by Kathryn Chatfield, MD. She is the director of the Cardiac Genetics and Aortopathy Program at Children's Hospital Colorado and specializes in clinical genetics and genomics, as well as cardiology. She is also an Associate Professor of Pediatric Cardiology at the University of Colorado School of Medicine. Some highlights from this episode include:  How to determine which kids should undergo a cardiac genetics workup and which ones may not need it  Understanding if these diseases are inherited, spontaneous or mutations  Why some kids with heart conditions are not seen until they are older  How primary care providers can interact with specialized genetics clinics   For more information on Children's Colorado, visit: childrenscolorado.org. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QVF865. CME/MOC/AAPA credit will be available until April 28, 2026.Achieving Next-Level HCM Care and Outcomes With Cardiac Myosin Inhibition: From Long-Term Clinical Evidence to Real-World Data In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Mended Hearts, Inc. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

Contributor: Ricky Dhaliwal, MD Educational Pearls: What factors are considered in a COVID-19 infection? The viral load: Understood as the impact of SARS-CoV-2 viral particles infecting host cell tissue itself (utilizing ACE-2 receptors). Pro-Inflammatory Response: Post-infection, the body's downstream systemic cytokine release (can be both normal or hyperactive, aka “cytokine storm”). What cardiac impacts have been observed with COVID-19? Arrhythmias: The mechanism of COVID-19 infection and arrhythmias is believed to be multifactorial. However, evidence suggests T-cell-mediated toxicity and cytokine storm may contribute to cardiac myocyte damage, precipitating proarrhythmias instead of direct viral entry. Bradycardia: Increased prevalence in patients with severe COVID-19 infection, but not associated with increased adverse outcomes. Atrial Fibrillation: Most common cardiac complication and risk factor for worsened outcomes in patients with COVID-19. Biggest associated risk is strokes, and may require heightened monitoring and anticoagulation therapy to mitigate stroke risk. Fibrosis of Cardiac Tissue: Similar to arrhythmias, believed to be inflammation-mediated in COVID-19. Fibrosis of cardiac tissue increases the risk that any arrhythmias that develop during infection may persist after the infection has resolved. Ventricular damage: Also inflammation mediated by an active infection and contributes to myocarditis. No evidence suggests that COVID-19 vaccination contributes to myocarditis.  Sinus node dysfunction induced by inflammation that may lead to or be similar to Postural Orthostatic Tachycardia Syndrome (POTS).  Big takeaway? Patients who have had or currently have COVID-19 are at an increased risk of developing arrhythmias and sustaining them post-infection. However, a majority of patients will recover. Due to atrial fibrillation being the most prevalent arrhythmia associated with COVID-19 infection, increased monitoring and potential anticoagulation therapy are required.  References Gopinathannair R, Olshansky B, Chung MK, Gordon S, Joglar JA, Marcus GM, et al. Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association. Circulation. 2024 Nov 19;150(21):e449–65. Khan Z, Pabani UK, Gul A, Muhammad SA, Yousif Y, Abumedian M, et al. COVID-19 Vaccine-Induced Myocarditis: A Systemic Review and Literature Search. Cureus. 14(7):e27408. Summarized by Dan Orbidan, OMS1 | Edited by Dan Orbidan & Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/

The Richmond Kickers delivered yet another heart-stopper in a wild 3-3 draw with Greenville. We break down all the drama — including Josh Kirkland's second straight brace, this time in front of Section O — and ask the big questions about the team's defensive issues and center back depth.Plus, we preview the next big test: a trip to Chattanooga, where the Kickers haven't won in nine attempts. Can they finally break the curse?

Send us a textWhy do our patients need pacemakers and what should you know about them? Written by Dr. Alyssa Chow (Internal Medicine Resident) and reviewed by Dr. Steve Montague (General Internal Medicine) and Dr. Aws Almufleh (Cardiology). Infographic Alyssa Chow and Sapirya Birk (Medical Student). Do you ever feel like you can't get ahead of charting? Freed AI has an AI driven scribe for you! You can try Freed for free right now by going to getfreed.ai. Listeners can use the INTERN50 code for $50 off their first month!Support the show

Sometimes the signs of heart trouble in women don't look like what we expect—they show up as hot flashes, brain fog, or even a racing heart. When I sat down with Dr. Jayne Morgan, an incredible Cardiologist and Women's Health Advocate, we talked about how these often-overlooked symptoms during menopause can actually be clues about what's going on with your heart. We're so used to brushing things off as “just hormones,” but Dr. Jayne explains why now is the time to tune in and take them seriously. Dr. Jayne —who's not only a top Cardiologist but also Vice President of Medical Affairs at Hello Heart—is passionate about making sure women get the full picture when it comes to heart health. She breaks down how estrogen protects your heart, what happens when those levels drop, and why menopause can be a turning point for understanding your risk. We also talked about what real, thorough heart testing should include (because yes, there's more to it than just cholesterol). Her approach is practical, empowering, and honestly—something every woman deserves to hear. Women need to feel empowered, not dismissed, when they bring up symptoms—and that starts with education. We're talking about prevention, clarity, and how to stop second-guessing what your body's trying to tell you. And in line with this we'd like to empower our women, mothers especially, we'll be having a  Mother's Day Sale from May 7-11 ‘25 where we'll get you up to 25% off with bundles of your favorite products. Check out https://dranna.com for more information.   Key Timestamps: [00:00:00] Introduction. [00:05:38] Estrogen's role in heart disease. [00:10:53] What entails an adequate cardiac workup? [00:12:28] Prevention of heart disease. [00:15:47] Aggressive management of risk factors. [00:19:25] Statin therapy, hormonal management, lowering cholesterol. [00:23:57] Pregnancy as a stress test. [00:29:00] The connection of diabetes and cardiovascular disease risk. [00:30:57] The relation of heart disease to early dementia and early stroke. [00:32:22] Who can have hormone replacement therapy?   Memorable Quotes: "All of these symptoms in perimenopause and menopause are actually biomarkers for heart disease, biomarkers for stroke." [00:06:47] – Dr. Jayne Morgan "Heart disease is the number one killer of women, and you, as a patient or a member of the public, do not have the ability to discern whether your palpitations that you're having at home are related to your perimenopause or related to a real heart issue that could pose an impending heart attack." [00:09:08] – Dr. Jayne Morgan   Links Mentioned: Mother's Day Sale from May 7- 11 ‘25 – https://dranna.com   Connect with Dr. Jayne Morgan: Linktree: https://linktr.ee/DrJayneMorgan Instagram: https://www.instagram.com/drjaynemorgan/ YouTube: https://www.youtube.com/@DrJayneMorgan LinkedIn: https://www.linkedin.com/in/jaynemorgan/   Connect with Dr. Anna Cabeca: Website: https://drannacabeca.com/pages/show Instagram: https://www.instagram.com/thegirlfrienddoctor/ YouTube: https://www.youtube.com/@thegirlfrienddoctor TikTok: https://www.tiktok.com/@drannacabeca   Produced by Evolved Podcasting: https://www.evolvedpodcasting.com

Gary and Shannon are bringing you the latest news from Washington, D.C in #SwampWatch. Trump's first 100 days will test the future of both the Republican and Democratic parties.TikTok Enema Trend. #WELLNESS: Waking up at 4 a.m. is not just for CEOs anymore. Eating ultraprocessed foods increases the risk of premature death. Champagne may protect the heart from cardiac arrest.

They did it AGAIN! Join Alex and Ty as they talk about an insane ending at The Friendly Confines and some other flurries of Cubs news and notes!Get your own Setup Man Swag: https://bit.ly/setupmanobvious

In this episode, I'll cover the root causes of reflux & share the most effective treatments. Tune in! Work with us! https://drruscio.com/virtual-clinic/ Product mentions:  Thiamega https://www.objectivenutrients.com/products/thiamega/ Vagustim https://vagustim.io/   Watch next

Contributor: Travis Barlock, MD Educational Pearls: Key clinical considerations when managing heart transplant patients due to their unique pathophysiology 1. Arrhythmias A transplanted heart is denervated, meaning it lacks autonomic nervous system innervation The lack of vagal tone results in an increased resting heart rate Adenosine can be used since it primarily slows conduction through the AV node  Atropine is ineffective in treating transplant bradyarrhythmia because its mechanism is to inhibit the vagus nerve - but the heart lacks vagal tone Allograft rejection can also cause tachycardia Consult transplant surgery - treatment is usually 500 mg methylprednisolone 2. Rejection Transplant patients are administered immunosuppressants Clinical presentation of acute rejection looks similar to heart failure with increased BNP, increased troponin, and pulmonary edema  Cardiac allograft vasculopathy is a form of chronic rejection Patients will not report chest pain due to denervated heart Symptoms are usually weakness and fatigue 3. High risk of infection due to immunosuppression Increased risk of infections which includes CMV, legionella, tuberculosis, etc Immunosuppressants have side effects such as acute kidney injury or pancytopenia 4. Radiographic Cardiomegaly A study found that radiographic cardiomegaly does not connote heart failure They hypothesized it is instead the result of a mismatch between the size of the transplanted heart and the space in the thoracic cavity  References Murphy JD, Mergo PJ, Taylor HM, Fields R, Mills RM Jr. Significance of radiographic cardiomegaly in orthotopic heart transplant recipients. AJR Am J Roentgenol. 1998 Aug;171(2):371-4. doi: 10.2214/ajr.171.2.9694454. PMID: 9694454. Park MH, Starling RC, Ratliff NB, McCarthy PM, Smedira NS, Pelegrin D, Young JB. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. J Heart Lung Transplant. 1999 Dec;18(12):1224-7. doi: 10.1016/s1053-2498(99)00098-4. PMID: 10612382. Pethig K, Heublein B, Wahlers T, Dannenberg O, Oppelt P, Haverich A. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J Heart Lung Transplant. 2004 Jan;23(1):61-6. doi: 10.1016/s1053-2498(03)00097-4. PMID: 14734128. Summarized by Meg Joyce, MS1 | Edited by Meg Joyce & Jorge Chalit, OMS3 Donate: https://emergencymedicalminute.org/donate/  

Varada Sethu joined Woman's Hour to talk about stepping into the iconic role of the Doctor Who companion. She tells Datshiane Navanagayam how she went from a guest star to landing the role of Belinda Chandra, why this character feels like her most personal yet, and what it means to her to bring cultural authenticity to the Tardis. With a background in science, classical dance, and Star Wars fandom, Varada brings a fresh energy to the Whoniverse.Grace Davidson was a teenager when she was diagnosed with a rare condition that meant she did not have a uterus. But, following a transplant using her sister's donated womb, she gave birth earlier this year to baby Amy. Nuala McGovern speaks to Isabel Quiroga, the surgeon who led the transplant team at the Churchill Hospital in Oxford, and to Lydia Brain, who is currently on the waiting list for a womb transplant.Emily MacGregor is a music historian and trombonist. After the sudden death of her father, a jazz guitarist, she found she wasn't able to bear the sound of music. The very thing that once connected them became a source of pain and silence. In her new book, While the Music Lasts, she explains how she reconnected with her father through the pieces left on his music stand, from tangos to Handel, Cádiz to Coltrane. She joined Nuala to talk about how she learnt to navigate grief and how she discovered the joy of music again.BBC2's Saving Lives in Cardiff is back on our screens from tonight. Based in the largest hospital in Wales, University Hospital in Cardiff, the series highlights the weight of difficult, sometimes life and death decisions surgeons make about who to prioritise next. The first episode follows Dr Indu Deglurkar, a cardiac surgeon, one of only 19 women in this role in the UK. She tells Nuala about the pressures and joys of her job.Have you been watching The White Lotus? The season three finale aired this week and one of the key themes that's had fans talking has been female friendship. It's left us wondering - is three a crowd? In the show the dynamic plays out between a trio of friends Jaclyn, Kate and Laurie, played by Michelle Monaghan, Leslie Bibb and Carrie Coon, who alternate between loving and loathing one another. So can friendships between three people work? TV critic Rachael Sigee and relationships writer at the Independent Olivia Petter joined Nuala McGovern.Presenter: Nuala McGovern Producer: Annette Wells Editor: Sarah Jane Griffiths

CardioNerds (Drs. Daniel Ambinder and Eunice Dugan) join Dr. Namrita Ashokprabhu, Dr. Yulith Roca Alvarez, and Dr. Mehmet Yildiz from The Christ Hospital. Expert commentary by Dr. Odayme Quesada. Audio editing by CardioNerds intern, Christiana Dangas. This episode highlights the pivotal role of cardiac MRI and functional testing in uncovering coronary vasospasm as an underlying cause of MINOCA. Cardiac MRI is crucial in evaluating myocardial infarction with nonobstructive coronary arteries (MINOCA) and diagnosing myocarditis, but findings must be interpreted within clinical context. A 58-year-old man with hypertension, hyperlipidemia, diabetes, a family history of cardiovascular disease, and smoking history presented with sudden chest pain, non-ST-elevation on EKG, and elevated troponin I (0.64 µg/L). Cardiac angiography revealed nonobstructive coronary disease, including a 40% stenosis in the LAD, consistent with MINOCA. Eight weeks later, another event (troponin I 1.18 µg/L) led to cardiac MRI findings suggesting myocarditis. Further history revealed episodic chest pain and coronary vasospasm, confirmed by coronary functional angiography showing severe vasoconstriction, resolved with nitroglycerin. Management included calcium channel blockers and long-acting nitrates, reducing symptoms. Coronary vasospasm is a frequent MINOCA cause and can mimic myocarditis on CMRI. Invasive coronary functional testing, including acetylcholine provocation testing, is indicated in suspicious cases.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Notes - Coronary Vasospasm What are the potential underlying causes of MINOCA (Myocardial Infarction with Non-Obstructive Coronary Arteries)?  Plaque Rupture: Plaque disruption, which includes plaque rupture, erosion, and calcified nodules, occurs as lipids accumulate in coronary arteries, leading to inflammation, necrosis, fibrosis, and calcification. Plaque rupture exposes the plaque to the lumen, causing thrombosis and thromboembolism, while plaque erosion results from thrombus formation without rupture and is more common in women and smokers. Intravascular imaging, such as IVUS and OCT, can detect plaque rupture and erosion, with studies showing plaque disruption as a frequent cause of MINOCA, particularly in women, though the true prevalence may be underestimated due to limited imaging coverage.  Coronary Vasospasm: Coronary vasospasm is characterized by nitrate-responsive chest pain, transient ischemic EKG changes, and >90% vasoconstriction during provocative testing with acetylcholine or ergonovine, due to hyper-reactivity in vascular smooth muscle. It is a common cause of MINOCA, with approximately half of MINOCA patients testing positive in provocative tests, and Asians are at a significantly higher risk than Whites. Smoking is a known risk factor for vasospasm. In contrast, traditional risk factors like sex, hypertension, and diabetes do not increase the risk, and vasospasm is associated with a 2.5–13% long-term risk of major adverse cardiovascular events (MACE).  Spontaneous Coronary Artery Dissection: Spontaneous coronary artery dissection (SCAD) involves the formation of a false lumen in epicardial coronary arteries without atherosclerosis, caused by either an inside-out tear or outside-in intramural hemorrhage. SCAD is classified into four types based on angiographic features, with coronary angiography being the primary diagnostic tool. However, in uncertain cases, advanced imaging like IVUS or OCT may be used cautiously. While the true prevalence is unclear due to missed diagnoses, SCAD is more common in women and is considered a cause of MINOCA when i...

In this 305th episode I welcome Dr. Eric Busch to the show as our next Master Clinician. He has been practicing anesthesiology at Oschner in New Orleans for 35 years and has done everything from Chronic Pain to Cardiac. We discuss what he's learned over the years and some of his favorite things to teach his trainees. Our Sponsors:* Check out Factor: https://factormeals.com/accrac50off* Check out Thrive Market: https://thrivemarket.com/ACCRACAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy